|Bid||16.76 x 3200|
|Ask||17.15 x 1100|
|Day's Range||16.26 - 17.33|
|52 Week Range||7.26 - 21.39|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||20.76|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.50|
Subscribe to Yahoo Finance Plus to view Fair Value for DVAX
The average of price targets set by Wall Street analysts indicates a potential upside of 92.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to potential market sizes and market share; market trends; impact of ACIP recommendations and timing of such impact; financial guidance and trends, including revenue, profitability, and sufficiency of current capitalization; timing and results of clinical trial starts and data readouts and potential future uses of CpG 1018 adjuvant. Joining me on the call today are Ryan Spencer, chief executive officer; Donn Casale, senior vice president of commercial; Rob Janssen, chief medical officer; and Kelly MacDonald, chief financial officer.